跳转至内容
Merck
CN
  • Assessment of cytochrome C oxidase dysfunction in the substantia nigra/ventral tegmental area in schizophrenia.

Assessment of cytochrome C oxidase dysfunction in the substantia nigra/ventral tegmental area in schizophrenia.

PloS one (2014-06-19)
Matthew W Rice, Kristen L Smith, Rosalinda C Roberts, Emma Perez-Costas, Miguel Melendez-Ferro
摘要

Perturbations in metabolism are a well-documented but complex facet of schizophrenia pathology. Optimal cellular performance requires the proper functioning of the electron transport chain, which is constituted by four enzymes located within the inner membrane of mitochondria. These enzymes create a proton gradient that is used to power the enzyme ATP synthase, producing ATP, which is crucial for the maintenance of cellular functioning. Anomalies in a single enzyme of the electron transport chain are sufficient to cause disruption of cellular metabolism. The last of these complexes is the cytochrome c oxidase (COX) enzyme, which is composed of thirteen different subunits. COX is a major site for oxidative phosphorylation, and anomalies in this enzyme are one of the most frequent causes of mitochondrial pathology. The objective of the present report was to assess if metabolic anomalies linked to COX dysfunction may contribute to substantia nigra/ventral tegmental area (SN/VTA) pathology in schizophrenia. We tested COX activity in postmortem SN/VTA from schizophrenia and non-psychiatric controls. We also tested the protein expression of key subunits for the assembly and activity of the enzyme, and the effect of antipsychotic medication on subunit expression. COX activity was not significantly different between schizophrenia and non-psychiatric controls. However, we found significant decreases in the expression of subunits II and IV-I of COX in schizophrenia. Interestingly, these decreases were observed in samples containing the entire rostro-caudal extent of the SN/VTA, while no significant differences were observed for samples containing only mid-caudal regions of the SN/VTA. Finally, rats chronically treated with antipsychotic drugs did not show significant changes in COX subunit expression. These findings suggest that COX subunit expression may be compromised in specific sub-regions of the SN/VTA (i.e. rostral regions), which may lead to a faulty assembly of the enzyme and a greater vulnerability to metabolic insult.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
Protease Inhibitor Cocktail, for use with mammalian cell and tissue extracts, DMSO solution
Sigma-Aldrich
HEPES, ≥99.5% (titration)
Supelco
蔗糖, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
3,3-二氨基联苯胺 四盐酸盐 水合物, ≥96%
Sigma-Aldrich
蔗糖, ACS reagent
Sigma-Aldrich
4-硝基苯基磷酸盐 二钠盐 六水合物, suitable for enzyme immunoassay, ≥99.0% (enzymatic)
Sigma-Aldrich
磷酸酶底物, 5 mg tablets
Sigma-Aldrich
抗肌动蛋白抗体,克隆C4, ascites fluid, clone C4, Chemicon®
Sigma-Aldrich
4-硝基苯基磷酸盐 二钠盐 六水合物, tablet
Sigma-Aldrich
4-硝基苯基磷酸盐 二钠盐 六水合物, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
蔗糖, puriss., meets analytical specification of Ph. Eur., BP, NF
Sigma-Aldrich
磷酸酶底物, powder
Sigma-Aldrich
4-硝基苯基磷酸盐 二钠盐 六水合物, tablet
Sigma-Aldrich
磷酸酶底物, 40 mg tablets
Sigma-Aldrich
硫酸镍(II)胺 六水合物, ≥98%
Sigma-Aldrich
4-硝基苯基磷酸盐 二钠盐 六水合物, tablet
Sigma-Aldrich
磷酸酶底物, 100 mg capsules
Sigma-Aldrich
细胞色素c氧化酶 来源于牛心脏, 5 mg protein/mL
Sigma-Aldrich
磷酸酶底物, 40 mg capsules
Sigma-Aldrich
磷酸酶底物, Suitable for manufacturing of diagnostic kits and reagents
Sigma-Aldrich
蔗糖, 99% (GC), Vetec, reagent grade